TempusAI (TEM) has embarked on long-term collaborations with AstraZeneca (AZN, Financial) and Pathos AI, Inc., focusing on the creation of a comprehensive multimodal foundation model in the field of oncology. This initiative is designed to facilitate the acquisition of biological and clinical insights, the discovery of new drug targets, and the development of innovative treatments for cancer. Tempus's de-identified oncology data will serve as the basis for this model.
Once the foundation model is complete, it will be accessible to all three partners, supporting their independent efforts to enhance patient care. As part of these agreements, Tempus will receive $200 million for data licensing and the development of the model. This alliance with AstraZeneca builds on a partnership that began in 2021, with both companies aiming to utilize Tempus's AI-driven platform and extensive multimodal data reserves to advance oncological therapeutic programs worldwide.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for AstraZeneca PLC (AZN, Financial) is $100.29 with a high estimate of $230.38 and a low estimate of $67.00. The average target implies an upside of 47.77% from the current price of $67.87. More detailed estimate data can be found on the AstraZeneca PLC (AZN) Forecast page.
Based on the consensus recommendation from 13 brokerage firms, AstraZeneca PLC's (AZN, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for AstraZeneca PLC (AZN, Financial) in one year is $88.55, suggesting a upside of 30.47% from the current price of $67.87. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the AstraZeneca PLC (AZN) Summary page.
